This ain't a company its a charity. Good cause but numbers are impossible to make work. Same stuff every year since 2014... more losses than revenue after all this time.
"Revenue from sale of goods increased by 33% over the same period prior year to $0.98 million. The Company reported an operating loss of $1.35 million (1H FY22: $1.22 million)."
"As at 30 September 2023, the Company had cash and cash equivalents of $0.8 million."
"At the August 2023 Annual General we indicated to shareholders that further growth funding is required to maintain the commercialisation momentum that we have generated over the past year."
Truscreen Group Limited (NZX/ASX:TRU) announces that for personal reasons, CEO, Dr. Beata Edling has resigned effective immediately and will assist in the transition to an interim CEO in the coming weeks. Beata has personal commitments to family in Poland and will be available to assist TruScreen on a consulting basis to further the business in Poland and central Europe.
Truscreen Group Limited (NZX/ASX:TRU) announces that for personal reasons, CEO, Dr. Beata Edling has resigned effective immediately and will assist in the transition to an interim CEO in the coming weeks. Beata has personal commitments to family in Poland and will be available to assist TruScreen on a consulting basis to further the business in Poland and central Europe.
Why IMHO did it take so long for this smoke and mirror outfit ?
TruScreen FY24 Preliminary Results
(all numbers in New Zealand Dollars)
Highlights
• SUS unit sales up 25% on prior year and device sales to distributors in line with prior year
• Major breakthrough in China with two peak organisations including TruScreen in their cervical cancer screening guidelines - China Obstetrics and Gynecology Association (COGA) Blue Paper and endorsement from the Chinese Society for Colposcopy and Cervical Pathology (CSCCP)
• Commercial operations commenced in Saudi Arabia and further progress in Zimbabwe
• In Vietnam TruScreen achieved inclusion on the Vietnamese Ministry Of Health (MOH) approved Technical List
• In Mexico the national regulator, Cofepris approved TruScreen access to the public health sector
• Developing new market opportunities in Uzbekistan, Indonesia, and Africa
• Successful capital raise and appointment of new Chief Executive Officer
• Improved Operations metrics.
o Sales up by 27%, led by SUS consumable sales increase of 25%.
o Operating loss reduced by 15%
o Cash outflow reduced by 9%
Bookmarks